Home › Funds › CIBRA Capital Ltd › APLS
CIBRA Capital Ltd position in APLS
APELLIS PHARMACEUTICALS INC
CIBRA Capital Ltd reported holding 50,000 shares of APLS (APELLIS PHARMACEUTICALS INC) in its Q1 2026 13F filing — a position valued at US$2.0M, representing 0.97% of its reported portfolio and ranking #22 among its reported holdings. CIBRA Capital Ltd first reported this position in Q1 2026.
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
How CIBRA Capital Ltd's APLS position evolved
CIBRA Capital Ltd first disclosed a stake in APLS in Q1 2026 at 50,000 shares (US$2.0M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 50.00K | $2.01M | New |
About APLS and 13F data
APLS (APELLIS PHARMACEUTICALS INC) is a company whose sector is not yet classified in our data. 2 other funds we track also report a position in APLS. Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
More on CIBRA Capital Ltd
FAQ
How long has CIBRA Capital Ltd held APLS?
CIBRA Capital Ltd has disclosed APLS holdings in 1 of the last 1 reported quarters, going back to Q1 2026.
What is CIBRA Capital Ltd's current position in APLS?
As of Q1 2026, CIBRA Capital Ltd holds 50.00K shares of APLS (APELLIS PHARMACEUTICALS INC), valued at $2.01M, representing 0.97% of its reported portfolio and ranking #22.
Has CIBRA Capital Ltd been buying or selling APLS?
In the latest 13F filing (Q1 2026), CIBRA Capital Ltd newly opened its position in APLS.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.